CEACAM6 is a novel biomarker in pancreatic adenocarcinoma and PanIN lesions |
| |
| Authors: | Duxbury Mark S Matros Evan Clancy Thomas Bailey Gerald Doff Michael Zinner Michael J Ashley Stanley W Maitra Anirban Redston Mark Whang Edward E |
| |
| Affiliation: | Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. |
| |
| Abstract: | OBJECTIVE: The purpose of this study was to test the hypothesis that CEACAM6 expression is an indicator of adverse pathologic features and clinical outcome in pancreatic adenocarcinoma. SUMMARY BACKGROUND DATA: Previously, we have demonstrated carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) to be an oncoprotein that plays an important role in the biology of pancreatic adenocarcinoma. Suppression of CEACAM6 expression reduces tumorigenesis and metastasis in vivo. METHODS: A tissue microarray was constructed using tumor specimens obtained from 89 consecutive patients who had undergone pancreatic resection for pancreatic adenocarcinoma with curative intent. A second microarray containing 54 pancreatic intraepithelial neoplasia (PanIN) lesions was constructed using tissues from a separate cohort of 44 patients. Both arrays were immunostained using a specific anti-CEACAM6 monoclonal antibody. Tumoral CEACAM6 expression was dichotomized into negative and positive immunoreactivity groups. The log-rank test was used to evaluate univariate associations of CEACAM6 expression with prognosis. Survival curves were derived using the Kaplan-Meier method. RESULTS: Tumoral CEACAM6 expression was detected in 82 (92%) pancreatic adenocarcinoma specimens. CEACAM6 expression was more prevalent in high-grade than in low-grade PanIN lesions (P = 0.0002). Negative tumoral CEACAM6 expression was associated with absence of lymph node metastases (P = 0.012), lower disease stage (P = 0.008), and longer postoperative survival (P = 0.047). CONCLUSIONS: CEACAM6 is a novel biomarker for pancreatic adenocarcinoma. CEACAM6 warrants further evaluation as both a prognostic factor and a therapeutic target in pancreatic cancer. |
| |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ |
|
